PUBLIC COMPANY
saveGILEAD SCIENCES INC
USupdated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Electra lights up with $350M IPO for pivotal immune-disease drug developmentElectra Therapeutics has exceeded its initial fundraising plans as it becomes the 26th biotech to debut publicly this year and outlines pivotal development plans for its monoclonal antibody ipsopru…biospace · 9h ago
- DPHARM: How to address the clinical trial enrollment crisis?Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.fiercebiotech · 1d ago
- Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPOPlus news about VaxThera, Sironax, Circle Pharma, Nutshell Therapeutics, Evopoint and Sensorion. Gilead’s HIV PrEP pact in Latin America: The California drugmaker said it formed an agreement with t…endpoints · 2d ago
- Sionna says good-bye to 46% of staffers, including execFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightThe year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.biopharma_dive · 3d ago
- Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagonCellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.fiercebiotech · 4d ago
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 7d ago
- Tyra shares slip as bladder cancer responses fall short of investor expectationsDespite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.biospace · 8d ago
- CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…fiercebiotech · 9d ago
- BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, accordin…biospace · 9d ago
comments(0)
5-min edit window · permanent after that